Condition
High-Risk Acute Myeloid Leukemia
Total Trials
4
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 2 (1)
Trial Status
Recruiting2
Not Yet Recruiting1
Withdrawn1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07237230Not ApplicableRecruitingPrimary
Clinical Study to Evaluate the Safety and Efficacy of γδ T Cells for the Prevention of Relapse After Allogeneic Transplantation in Patients With High-risk Acute Myeloid Leukemia
NCT07183878Not ApplicableRecruiting
Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)
NCT06686173Not Yet RecruitingPrimary
Effect of Donor Chose on the Outcomes of GVHD Prophylaxis Underwent the Combined Treatment of ATG/PTCy for Haplo-HSCT
NCT03365661Phase 2WithdrawnPrimary
QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML
Showing all 4 trials